{"preliminary_commentary":{"by_channel":{"x_thread":18,"youtube":3,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT07383441\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"BioFront","nct_id":"NCT07383441","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=biofront-nct07383441. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"See Detailed Description","label":"Arm 1 (MO-03, SOC immunotherapy)","type":"EXPERIMENTAL"},{"description":"See Detailed Description","label":"Arm 2 (placebo, SOC immunotherapy)","type":"PLACEBO_COMPARATOR"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2034-01-31","type":"ESTIMATED"},"conditions":["Advanced Clear Cell Renal Cell Carcinoma","Metastatic Clear Cell Renal Cell Carcinoma","Stage III Renal Cell Cancer AJCC v8","Stage IV Renal Cell Cancer AJCC v8"],"enrollment":{"count":718,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Axitinib","otherNames":["AG 013736","AG-013736","AG013736","Inlyta"],"type":"DRUG"},{"name":"Biospecimen Collection","otherNames":["Biological Sample Collection","Biospecimen Collected","Specimen Collection"],"type":"PROCEDURE"},{"name":"Bone Scan","otherNames":["Bone Scintigraphy"],"type":"PROCEDURE"},{"name":"Cabozantinib","otherNames":[],"type":"DRUG"},{"name":"Clostridium butyricum CBM 588 Probiotic Strain","otherNames":["C. butyricum CBM 588 Probiotic Strain","C. butyricum MIYAIRI Strain","C. butyricum Strain MIYAIRI 588","CBM 588","CBM588","Clostridium butyricum MIYAIRI 588","Clostridium butyricum MIYAIRI 588 Probiotic Strain","CLOSTRIDIUM BUTYRICUM MIYAIRI 588 STRAIN","MIYAIRI 588","MIYAIRI 588 Strain of C. butyricum"],"type":"DRUG"},{"name":"Computed Tomography","otherNames":["CAT","CAT Scan","Computed Axial Tomography","Computerized Axial Tomography","Computerized axial tomography (procedure)","Computerized Tomography","Computerized Tomography (CT) scan","CT","CT Scan","Diagnostic CAT Scan","Diagnostic CAT Scan Service Type","tomography"],"type":"PROCEDURE"},{"name":"Ipilimumab","otherNames":["Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody","BMS 734016","BMS-734016","BMS734016","Ipilimumab Biosimilar CS1002","MDX 010","MDX-010","MDX-CTLA4","MDX010","Yervoy"],"type":"BIOLOGICAL"},{"name":"Lenvatinib","otherNames":["E 7080","E-7080","E7080","ER-203492-00","Multi-Kinase Inhibitor E7080"],"type":"DRUG"},{"name":"Magnetic Resonance Imaging","otherNames":["Magnetic Resonance","Magnetic Resonance Imaging (MRI)","Magnetic resonance imaging (procedure)","Magnetic Resonance Imaging Scan","Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance","MR","MR Imaging","MRI","MRI Scan","MRIs","NMR Imaging","NMRI","Nuclear Magnetic Resonance Imaging","sMRI","Structural MRI"],"type":"PROCEDURE"},{"name":"Nivolumab","otherNames":["ABP 206","BCD-263","BMS 936558","BMS-936558","BMS936558","CMAB819","MDX 1106","MDX-1106","MDX1106","NIVO","Nivolumab Biosimilar ABP 206","Nivolumab Biosimilar BCD-263","Nivolumab Biosimilar CMAB819","ONO 4538","ONO-4538","ONO4538","Opdivo"],"type":"BIOLOGICAL"},{"name":"Nivolumab and Recombinant Human Hyaluronidase","otherNames":["Hyaluronidase-nvhy and Nivolumab","Hyaluronidase/Nivolumab","Nivolumab and Hyaluronidase-nvhy","Nivolumab and rHuPH20","Nivolumab/Recombinant Human Hyaluronidase","Nivolumab/rHuPH20","Opdivo Qvantig"],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":["BCD-201","GME 751","GME751","Keytruda","Lambrolizumab","MK 3475","MK-3475","MK3475","Pembrolizumab Biosimilar BCD-201","Pembrolizumab Biosimilar GME751","Pembrolizumab Biosimilar QL2107","Pembrolizumab Biosimilar RPH-075","Pembrolizumab Biosimilar SB27","QL2107","RPH 075","RPH-075","RPH075","SB 27","SB-27","SB27","SCH 900475","SCH-900475","SCH900475"],"type":"BIOLOGICAL"},{"name":"Placebo Administration","otherNames":[],"type":"DRUG"}],"last_update":"2026-06-11","lead_sponsor":"SWOG Cancer Research Network","official_title":"Phase III Double Blinded Trial of Immune-Based Therapy With a Live Biotherapeutic MO-03 or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma [BioFront Trial]","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2033-01-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-free survival (PFS)","timeFrame":"From date of randomization to date of first documentation of progression, or death due to any cause, assessed up to 5 years"}],"references":[],"start_date":{"date":"2026-06-05","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer","url":"https://clinicaltrials.gov/study/NCT07383441"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/biofront-nct07383441"}